Exploring Cabozantinib Plus Nivolumab: A Breakthrough in Advanced Angiosarcoma – An Interview with Dr. Gary Schwartz

In this enlightening interview, esteemed Oncologist Gary Schwartz, MD discusses the promising development and potential of Cabozantinib plus Nivolumab as a therapeutic approach in advanced Angiosarcoma. Drawing from his extensive experience and recent clinical trials, Dr. Schwartz delves into the efficacy and safety profile of this potent combination. He shares insights on how this regimen has shown substantial improvements in response rates and progression-free survival, and its potential role in reshaping the treatment landscape for patients with advanced Angiosarcoma. The interview concludes with a discussion on future directions, emphasizing the importance of continued research to unlock the full potential of this combination therapy.